ACOG
Alpha Cognition Inc

341
Mkt Cap
$115.45M
Volume
110,631.00
52W High
$11.54
52W Low
$3.75
PE Ratio
-3.89
ACOG Fundamentals
Price
$5.31
Prev Close
$5.83
Open
$5.90
50D MA
$6.38
Beta
0.00
Avg. Volume
98,723.05
EPS (Annual)
-$2.02
P/B
2.54
Loading...
Loading...
News
all
press releases
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that...
Business Wire·13d ago
News Placeholder
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Zacks·26d ago
News Placeholder
Alpha Cognition (NASDAQ:ACOG) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Alpha Cognition from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·29d ago
News Placeholder
Alpha Cognition (NASDAQ:ACOG) Announces Earnings Results, Beats Estimates By $0.16 EPS
Alpha Cognition (NASDAQ:ACOG - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate...
MarketBeat·29d ago
News Placeholder
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +30.23% and +39.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company) today announced its financial results for the third quarter ended September 30, 2025, and provided an operational update. Our...
Business Wire·1mo ago
News Placeholder
MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth
Medtronic's Q2 results may see a lift from solid Cardiovascular momentum and strong Diabetes segment growth.
Zacks·1mo ago
News Placeholder
Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial...
Business Wire·2mo ago
News Placeholder
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it...
Business Wire·2mo ago

Latest ACOG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.